Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk ALL
In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure...
Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC
In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associate...
FDA Approves Trastuzumab Biosimilar Trastuzumab-strf
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of...
FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
On April 29, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak) for patients with recurrent...
USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer. The USPSTF now recommends...
Susan Faye Dent: Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?
Kelly Hewitt and Laura J. Esserman: Reframing DCIS as an Opportunity for Cancer Prevention
Garth Strohbehn, Allen Lichter, and Mark Ratain: Sotorasib, the Poster Child for Project Optimus
Kevin B. Knopf and Charles L. Bennett: Generic Drug Shortages and Essential Cancer Medicines
Stuart M. Lichtman: All Adult Oncologists Are Geriatric Oncologists
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Targeting Rare, Actionable Alterations in Advanced Non–Small Cell Lung Cancer
Efficacy of Platinum Chemotherapy vs Capecitabine for Basal-Like Triple-Negative Breast Cancer
About 80% of triple-negative breast cancers are classified as the subtype basal-like. Typically, patients with triple-negative breast cancer receive chemotherapy before surgery. The presence of residual cancer in the breast after chemotherapy signals a higher likelihood that the cancer will...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Sotorasib for KRAS G12C–Mutated NSCLC: Overall Survival and Exploratory Subgroup Analyses
Results from the phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and a median overall survival of 12.5 months in previously treated patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC)....
Predictors of Emergency Department Visits After a New Diagnosis of Cancer
In a retrospective cohort study reported in JCO Oncology Practice, Hong et al found that prior frequent emergency department use was the strongest predictor of postdiagnosis emergency department visits among patients with a new diagnosis of cancer. Study Details The study involved data from...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Ponatinib/Blinatumomab Demonstrates High Rates of Complete Molecular Response in Philadelphia Chromosome–Positive ALL
The combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). The study—presented by Nicholas J. Short, MD, and colleagues during the 2021 ASCO...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
